A recent study highlighted that a “proteogenomics” approach for 122 primary breast cancers, when compared to standard BC diagnoses, provided a more detailed analysis of the ERBB2 amplicon, defined better tumor subsets that could benefit from immune checkpoint therapy and allowed a more accurate assessment of the Rb status for the prediction of CDK4/6 inhibitor responsiveness [119]. The gene discussed is ERBB2; the disease is neoplasm.